Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Afroditi Boutou
 + 1096 word(s) 1096 2021-04-25 10:21:38

Video Upload Options

We provide professional Video Production Services to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Boutou, A. Systemic Sclerosis-Related Pulmonary Arterial Hypertension. Encyclopedia. Available online: https://encyclopedia.pub/entry/9687 (accessed on 18 November 2024).
Boutou A. Systemic Sclerosis-Related Pulmonary Arterial Hypertension. Encyclopedia. Available at: https://encyclopedia.pub/entry/9687. Accessed November 18, 2024.
Boutou, Afroditi. "Systemic Sclerosis-Related Pulmonary Arterial Hypertension" Encyclopedia, https://encyclopedia.pub/entry/9687 (accessed November 18, 2024).
Boutou, A. (2021, May 17). Systemic Sclerosis-Related Pulmonary Arterial Hypertension. In Encyclopedia. https://encyclopedia.pub/entry/9687
Boutou, Afroditi. "Systemic Sclerosis-Related Pulmonary Arterial Hypertension." Encyclopedia. Web. 17 May, 2021.
Systemic Sclerosis-Related Pulmonary Arterial Hypertension
Edit
This entry is adapted from the peer-reviewed paper 10.3390/jcm10071528

Systemic sclerosis (SSc)-related pulmonary arterial hypertension (SSc-PAH) is a leading cause of mortality in SSc. The extent of peripheral microvasculopathy assessed through nailfold capillaroscopy might correlate with the presence of PAH in SSc patients. 

pulmonary arterial hypertension systemic sclerosis nailfold capillaroscopy

1. Introduction

Systemic sclerosis (SSc) is an autoimmune connective tissue disease characterized by microvascular damage and extensive skin and visceral organ fibrosis. These mechanisms synergistically lead to severe internal organ impairment and, subsequently, to increased mortality [1]. Despite better understanding of its pathogenesis, SSc remains a devastating disease with a calculated pooled standardized mortality ratio of 3.5 [2], predominantly due to cardiopulmonary involvement [3]. Pulmonary arterial hypertension related to SSc (SSc-PAH) occurs in approximately 10–15% of SSc individuals and accounts for a significant proportion of early mortality in this population [4][5]. Prompt diagnosis of SSc-PAH and initiation of targeted therapy are of paramount importance [6][7][8], since timely intervention has been associated with improved survival [9].

Nailfold capillaroscopy is a non-invasive diagnostic tool in SSc, allowing clinicians to assess microvascular damage in early stages of the disease [10]. It is included in the latest classification criteria for SSc [11] as well as in the criteria for the very early diagnosis of SSc (VEDOSS) [12]. Recently, nailfold capillaroscopy has also emerged as a potential surrogate marker of SSc progression [13] as several studies have demonstrated that microvascular alterations might correlate with visceral organ involvement, particularly vascular complications such as PAH [13][14][15]. The concept that peripheral microcirculatory changes may be suggestive of a more systemic vascular disorder including pulmonary vasculature is gaining ground [16][17].

2. Nailfold Capillaroscopy in Systemic Sclerosis Patients with and without Pulmonary Arterial Hypertension

We demonstrated that capillary density was reduced in SSc-PAH patients and this effect was accentuated when RHC was utilized for PAH diagnosis. Accordingly, SSc-PAH individuals had more than thirty times higher likelihood of vascular deletion score greater than 1. Increased capillary loop width, severe scleroderma pattern, and nailfold capillaroscopy rating scale score greater than 1 were also associated with the existence of PAH. The results of our analysis indicate that despite overall microvascular injury in SSc patients, those with SSc-PAH present with more advanced changes in peripheral microcirculation.

Microvasculopathy represents a fundamental part of SSc pathogenesis, leading to several clinical manifestations such as Raynaud’s phenomenon and digital ulcers [18]. Multiple cohort studies have postulated that nailfold capillaroscopic abnormalities correlate with the severity of organ involvement including PAH [13][19][20][21]. Indeed, in a 3-year longitudinal study, progressive loss of capillaries, presence of angiogenesis, and late scleroderma pattern were identified as markers for the occurrence of PAH [20]. SSc-PAH has also been associated with higher scores for capillary loss and capillary disorganization [19]. Additionally, it has been reported that increasing echocardiographically derived systolic pulmonary arterial pressure correlates with the severity of scleroderma pattern [21]. Furthermore, a diagnostic accuracy meta-analysis assessing the value of NVC in the diagnosis of SSc-PAH demonstrated that lower capillary density and increased capillary loop width could potentially detect patients with SSc-PAH [22]. These findings are consistent with the results of our study, suggesting that a higher degree of peripheral nailfold microangiopathy is more common in SSc-PAH, supporting the hypothesis that peripheral microvascular changes may parallel with similar abnormalities in the pulmonary vascular tree.

Interestingly, changes in peripheral microcirculation have also been observed in other forms of pulmonary hypertension [23][24][25][26][27][28]. Hofstee et al. suggested that capillary density is significantly reduced in individuals with idiopathic PAH compared to healthy controls and inversely correlated with the severity of idiopathic PAH [23]. These findings have later been confirmed by other studies, which additionally reported a significant increase in capillary loop width in idiopathic PAH patients [24][25]. Similar patterns of capillaroscopic abnormalities have been reported in chronic thromboembolic pulmonary hypertension [25] and in connective tissue disease-related PAH beyond SSc [27]. For example, the incidence of scleroderma pattern as well as high vascular deletion score were established as independent predictors of PAH in systemic lupus erythematous patients [27]. Recently, a cross-sectional study showed that patients with Eisenmenger syndrome had a reduced capillary density, an increased loop width and more abnormal capillaries than age- and sex-matched healthy controls. NVC shape abnormalities in Eisenmenger syndrome were positively correlated with N-terminal-pro brain natriuretic peptide and negatively associated with estimated glomerular filtration rate [28]. The presence of reduced capillary density and increased capillary width across the whole spectrum of pre-capillary PAH might indicate that besides SSc-associated microangiopathy, PAH may serve as an additional contributing factor to the pronounced microvascular abnormalities observed in SSc-PAH compared to SSc-noPAH.

Early detection of SSc-PAH remained an unmet need for years. According to recent studies from European PAH registries, the percentage of SSc-PAH presenting with New York Heart Association (NYHA) functional class III or IV symptoms at the time of diagnosis reaches 75% [29][30], and remains approximately as high as 30 years ago [31]. Recently, significant progress has been marked with the development of risk assessment algorithms such as the DETECT and Australian Scleroderma Interest Group (ASIG) algorithm as well as the latest European Society of Cardiology (ESC)/European Respiration Society (ERS) guidelines [32][33][34]. Studies have demonstrated that the implementation of these algorithms annually in asymptomatic patients reduces or even eliminates missed PAH cases [35][36][37]. However, the high referral rate for RHC as well as the unclear cost-effectiveness of yearly screening in asymptomatic patients constitute major throwbacks, leading clinicians to poor adherence to PAH screening guidelines [34][38]. Since nailfold capillaroscopy seems to correlate with the presence of PAH, it could potentially navigate clinicians in PAH risk stratification and enhance the performance characteristics of current algorithms, whilst reducing the rate of needless RHCs.

3. Future Perspectives and Conclusions

The results of our analysis suggest that SSc-PAH individuals present with worsening stages of peripheral microangiopathy compared to SSc-noPAH patients, suggesting a more widespread microvasculopathy in these individuals. Future research should explore whether capillaroscopic characteristics are able to identify patients at high risk for developing PAH. Large, well-designed, multi-center, adequately powered RHC-based studies, encompassing sequential nailfold capillaroscopy for longitudinal evaluation of microcirculation, are needed to establish nailfold capillaroscopy as a reliable indicator of pulmonary vasculopathy and determine its performance as part of current screening algorithms in patients at higher risk for SSc-PAH. Such approaches require prespecified methodology for the evaluation of certain capillaroscopic parameters and the application of a homogeneous nailfold capillaroscopy scoring system in order to ensure the validity of measurements [39]. Toward this direction, new automated systems for the calculation of capillary density in NVC images have been introduced with promising results in terms of reliability and time consumption [40]. A potential validation of these findings would showcase the value of nailfold capillaroscopy, particularly NVC, due to the shorter training duration it requires and the better image quality it offers [39], as a useful adjunct for PAH screening and a helpful guide for clinical decision making.

References

  1. LeRoy, E.C. Systemic Sclerosis. A Vascular Perspective. Rheum. Dis. Clin. N. Am. 1996, 22, 675–694.
  2. Elhai, M.; Meune, C.; Avouac, J.; Kahan, A.; Allanore, Y. Trends in Mortality in Patients with Systemic Sclerosis over 40 Years: A Systematic Review and Meta-Analysis of Cohort Studies. Rheumatology 2012, 51, 1017–1026.
  3. Nihtyanova, S.I.; Tang, E.C.; Coghlan, J.G.; Wells, A.U.; Black, C.M.; Denton, C.P. Improved Survival in Systemic Sclerosis Is Associated with Better Ascertainment of Internal Organ Disease: A Retrospective Cohort Study. QJM Int. J. Med. 2010, 103, 109–115.
  4. Tyndall, A.J.; Bannert, B.; Vonk, M.; Airò, P.; Cozzi, F.; Carreira, P.E.; Bancel, D.F.; Allanore, Y.; Müller-Ladner, U.; Distler, O.; et al. Causes and Risk Factors for Death in Systemic Sclerosis: A Study from the EULAR Scleroderma Trials and Research (EUSTAR) Database. Ann. Rheum. Dis. 2010, 69, 1809–1815.
  5. Mukerjee, D.; St, G.; Coleiro, B.; Knight, C.; Denton, C.; Davar, J.; Black, C.; Coghlan, J. Prevalence and Outcome in Systemic Sclerosis Associated Pulmonary Arterial Hypertension: Application of a Registry Approach. Ann. Rheum. Dis. 2003, 62, 1088–1093.
  6. Phung, S.; Strange, G.; Chung, L.P.; Leong, J.; Dalton, B.; Roddy, J.; Deague, J.; Playford, D.; Musk, M.; Gabbay, E. Prevalence of Pulmonary Arterial Hypertension in an Australian Scleroderma Population: Screening Allows for Earlier Diagnosis. Intern. Med. J. 2009, 39, 682–691.
  7. Weatherald, J.; Montani, D.; Jevnikar, M.; Jaïs, X.; Savale, L.; Humbert, M. Screening for Pulmonary Arterial Hypertension in Systemic Sclerosis. Eur. Respir. Rev. 2019, 28, 190023.
  8. Demerouti, E.; Tsangaris, I.; Dimitroulas, T.; Giannakoulas, G.; Katsimpri, P.; Mitrouska, I.; Orfanos, S.; Skoularigkis, I.; Voulgari, P.; Sfikakis, P. Pulmonary Arterial Hypertension in Connective Tissue Disorders: The Emerging Role of Screening and Early Diagnosis. A Position Paper for Greek Rheumatologists. Mediterr. J. Rheumatol. 2019, 30, 90–93.
  9. Humbert, M.; Yaici, A.; de Groote, P.; Montani, D.; Sitbon, O.; Launay, D.; Gressin, V.; Guillevin, L.; Clerson, P.; Simonneau, G.; et al. Screening for Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis: Clinical Characteristics at Diagnosis and Long-Term Survival. Arthritis Rheum. 2011, 63, 3522–3530.
  10. Lambova, S.N.; Muller-Ladner, U. Nailfold Capillaroscopy Within and Beyond the Scope of Connective Tissue Diseases. Curr. Rheumatol. Rev. 2018, 14, 12–21.
  11. van den Hoogen, F.; Khanna, D.; Fransen, J.; Johnson, S.R.; Baron, M.; Tyndall, A.; Matucci-Cerinic, M.; Naden, R.; Riemekasten, G.; Carreira, P.; et al. Classification Criteria for Systemic Sclerosis: An ACR-EULAR Collaborative Initiative. Arthritis Rheum. 2013, 65, 2737–2747.
  12. Vasile, M.; Avouac, J.; Sciarra, I.; Stefanantoni, K.; Iannace, N.; Cravotto, E.; Valesini, G.; Allanore, Y.; Riccieri, V. From VEDOSS to Established Systemic Sclerosis Diagnosis According to ACR/EULAR 2013 Classification Criteria: A French-Italian Capillaroscopic Survey. Clin. Exp. Rheumatol. 2018, 36, 82–87.
  13. Ingegnoli, F.; Ardoino, I.; Boracchi, P.; Cutolo, M.; Airò, P.; Ananieva, L.P.; Ancuta, C.; Andrade, L.E.; Becvar, R.; Benenati, A.; et al. Nailfold Capillaroscopy in Systemic Sclerosis: Data from the EULAR Scleroderma Trials and Research (EUSTAR) Database. Microvasc. Res. 2013, 89, 122–128.
  14. Caramaschi, P.; Canestrini, S.; Martinelli, N.; Volpe, A.; Pieropan, S.; Ferrari, M.; Bambara, L.M.; Carletto, A.; Biasi, D. Scleroderma Patients Nailfold Videocapillaroscopic Patterns Are Associated with Disease Subset and Disease Severity. Rheumatology 2007, 46, 1566–1569.
  15. Zanatta, E.; Famoso, G.; Boscain, F.; Montisci, R.; Pigatto, E.; Polito, P.; Schiavon, F.; Iliceto, S.; Cozzi, F.; Doria, A.; et al. Nailfold Avascular Score and Coronary Microvascular Dysfunction in Systemic Sclerosis: A Newsworthy Association. Autoimmun. Rev. 2019, 18, 177–183.
  16. Emrani, Z.; Karbalaie, A.; Fatemi, A.; Etehadtavakol, M.; Erlandsson, B.-E. Capillary Density: An Important Parameter in Nailfold Capillaroscopy. Microvasc. Res. 2017, 109, 7–18.
  17. Soulaidopoulos, S.; Triantafyllidou, E.; Garyfallos, A.; Kitas, G.D.; Dimitroulas, T. The Role of Nailfold Capillaroscopy in the Assessment of Internal Organ Involvement in Systemic Sclerosis: A Critical Review. Autoimmun. Rev. 2017, 16, 787–795.
  18. Allanore, Y.; Simms, R.; Distler, O.; Trojanowska, M.; Pope, J.; Denton, C.P.; Varga, J. Systemic Sclerosis. Nat. Rev. Dis. Prim. 2015, 1, 15002.
  19. Sulli, A.; Pizzorni, C.; Smith, V.; Zampogna, G.; Ravera, F.; Cutolo, M. Timing of Transition between Capillaroscopic Patterns in Systemic Sclerosis. Arthritis Rheum. 2012, 64, 821–825.
  20. Avouac, J.; Lepri, G.; Smith, V.; Toniolo, E.; Hurabielle, C.; Vallet, A.; Amrouche, F.; Kahan, A.; Cutolo, M.; Allanore, Y. Sequential Nailfold Videocapillaroscopy Examinations Have Responsiveness to Detect Organ Progression in Systemic Sclerosis. Semin. Arthritis Rheum. 2017, 47, 86–94.
  21. Sulli, A.; Paolino, S.; Pizzorni, C.; Ferrari, G.; Pacini, G.; Pesce, G.; Carmisciano, L.; Smith, V.; Cutolo, M. Progression of Nailfold Capillaroscopic Patterns and Correlation with Organ Involvement in Systemic Sclerosis: A 12 Year Study. Rheumatology 2020, 59, 1051–1058.
  22. Xia, Z.; Wang, G.; Xiao, H.; Guo, S.; Liu, Y.; Meng, F.; Liu, D.; Li, G.; Zong, L. Diagnostic Value of Nailfold Videocapillaroscopy in Systemic Sclerosis Secondary Pulmonary Arterial Hypertension: A Meta-Analysis. Intern. Med. J. 2018, 48, 1355–1359.
  23. Hofstee, H.; Noordegraaf, A.V.; E Voskuyl, A.; Dijkmans, B.; Postmus, P.; Smulders, Y.; Serne, E. Nailfold Capillary Density Is Associated with the Presence and Severity of Pulmonary Arterial Hypertension in Systemic Sclerosis. Ann. Rheum. Dis. 2009, 68, 191–195.
  24. Corrado, A.; Correale, M.; Mansueto, N.; Monaco, I.; Carriero, A.; Mele, A.; Colia, R.; Di Biase, M.; Cantatore, F.P. Nailfold Capillaroscopic Changes in Patients with Idiopathic Pulmonary Arterial Hypertension and Systemic Sclerosis-Related Pulmonary Arterial Hypertension. Microvasc. Res. 2017, 114, 46–51.
  25. Arvanitaki, A.; Giannakoulas, G.; Triantafyllidou, E.; Feloukidis, C.; Boutou, A.K.; Garyfallos, A.; Karvounis, H.; Dimitroulas, T. Peripheral Microangiopathy in Precapillary Pulmonary Hypertension: A Nailfold Video Capillaroscopy Prospective Study. Respir. Res. 2021, 22, 27.
  26. Arvanitaki, A.; Giannakoulas, G.; Triantafyllidou, E.; Karvounis, H.; Garyfallos, A.; Kitas, G.; Dimitroulas, T. Nailfold Videocapillaroscopy: A Novel Possible Surrogate Marker for the Evaluation of Peripheral Microangiopathy in Pulmonary Arterial Hypertension. Scand. J. Rheumatol. 2020, 1–10.
  27. Donnarumma, J.F.S.; Ferreira, E.V.M.; Ota-Arakaki, J.; Kayser, C. Nailfold Capillaroscopy as a Risk Factor for Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus Patients. Adv. Rheumatol. 2019, 59, 1.
  28. Arvanitaki, A.; Giannakoulas, G.; Triantafyllidou, E.; Feloukidis, C.; Boutou, A.; Garyfallos, A.; Karvounis, H.; Diller, G.-P.; Gatzoulis, M.A.; Dimitroulas, T. Peripheral Microangiopathy in Eisenmenger Syndrome: A Nailfold Video Capillaroscopy Study. Int. J. Cardiol. 2021.
  29. Hoeper, M.M.; Kramer, T.; Pan, Z.; Eichstaedt, C.A.; Spiesshoefer, J.; Benjamin, N.; Olsson, K.M.; Meyer, K.; Vizza, C.D.; Vonk-Noordegraaf, A.; et al. Mortality in Pulmonary Arterial Hypertension: Prediction by the 2015 European Pulmonary Hypertension Guidelines Risk Stratification Model. Eur. Respir. J. 2017, 50, 1700740.
  30. Weatherald, J.; Boucly, A.; Launay, D.; Cottin, V.; Prévot, G.; Bourlier, D.; Dauphin, C.; Chaouat, A.; Savale, L.; Jaïs, X.; et al. Haemodynamics and Serial Risk Assessment in Systemic Sclerosis Associated Pulmonary Arterial Hypertension. Eur. Respir. J. 2018, 52, 1800678.
  31. Rich, S.; Dantzker, D.R.; Ayres, S.M.; Bergofsky, E.H.; Brundage, B.H.; Detre, K.M.; Fishman, A.P.; Goldring, R.M.; Groves, B.M.; Koerner, S.K. Primary Pulmonary Hypertension. A National Prospective Study. Ann. Intern. Med. 1987, 107, 216–223.
  32. Galiè, N.; Humbert, M.; Vachiery, J.-L.; Gibbs, S.; Lang, I.; Torbicki, A.; Simonneau, G.; Peacock, A.; Noordegraaf, A.V.; Beghetti, M.; et al. 2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur. Respir. J. 2015, 46, 903–975.
  33. Coghlan, J.G.; Denton, C.P.; Grünig, E.; Bonderman, D.; Distler, O.; Khanna, D.; Müller-Ladner, U.; Pope, J.E.; Vonk, M.C.; Doelberg, M.; et al. Evidence-Based Detection of Pulmonary Arterial Hypertension in Systemic Sclerosis: The DETECT Study. Ann. Rheum. Dis. 2014, 73, 1340–1349.
  34. Morrisroe, K.; Stevens, W.; Sahhar, J.; Rabusa, C.; Nikpour, M.; Proudman, S.; Hill, C.; Lester, S.; Nash, P.; Ngian, G.; et al. Epidemiology and Disease Characteristics of Systemic Sclerosis-Related Pulmonary Arterial Hypertension: Results from a Real-Life Screening Programme. Arthritis Res. Ther. 2017, 19, 42.
  35. Hao, Y.; Thakkar, V.; Stevens, W.; Morrisroe, K.; Prior, D.; Rabusa, C.; Youssef, P.; Gabbay, E.; Roddy, J.; Walker, J.; et al. A Comparison of the Predictive Accuracy of Three Screening Models for Pulmonary Arterial Hypertension in Systemic Sclerosis. Arthritis Res. Ther. 2015, 17, 7.
  36. Guillén-Del Castillo, A.; Callejas-Moraga, E.L.; García, G.; Rodríguez-Palomares, J.F.; Román, A.; Berastegui, C.; López-Meseguer, M.; Domingo, E.; Fonollosa-Plá, V.; Simeón-Aznar, C.P. High Sensitivity and Negative Predictive Value of the DETECT Algorithm for an Early Diagnosis of Pulmonary Arterial Hypertension in Systemic Sclerosis: Application in a Single Center. Arthritis Res. Ther. 2017, 19, 135.
  37. Vandecasteele, E.; Drieghe, B.; Melsens, K.; Thevissen, K.; de Pauw, M.; Deschepper, E.; Decuman, S.; Bonroy, C.; Piette, Y.; de Keyser, F.; et al. Screening for Pulmonary Arterial Hypertension in an Unselected Prospective Systemic Sclerosis Cohort. Eur. Respir. J. 2017, 49, 1602275.
  38. Pauling, J.D.; McHugh, N.J. Evaluating Factors Influencing Screening for Pulmonary Hypertension in Systemic Sclerosis: Does Disparity between Available Guidelines Influence Clinical Practice? Clin. Rheumatol. 2012, 31, 357–361.
  39. Smith, V.; Herrick, A.L.; Ingegnoli, F.; Damjanov, N.; de Angelis, R.; Denton, C.P.; Distler, O.; Espejo, K.; Foeldvari, I.; Frech, T.; et al. Standardisation of Nailfold Capillaroscopy for the Assessment of Patients with Raynaud’s Phenomenon and Systemic Sclerosis. Autoimmun. Rev. 2020, 19, 102458.
  40. Cutolo, M.; Trombetta, A.C.; Melsens, K.; Pizzorni, C.; Sulli, A.; Ruaro, B.; Paolino, S.; Deschepper, E.; Smith, V. Automated Assessment of Absolute Nailfold Capillary Number on Videocapillaroscopic Images: Proof of Principle and Validation in Systemic Sclerosis. Microcirculation 2018, 25, e12447.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Cardiac & Cardiovascular Systems
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Afroditi Boutou
View Times: 392
Revision: 1 time (View History)
Update Date: 17 May 2021
Table of Contents
    1000/1000
    Hot Most Recent
    ScholarVision Creations
    Feedback